Skip to main content
Fig. 2 | Critical Care

Fig. 2

From: ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock

Fig. 2

Early Cardiovascular Endpoints for Angiotensin-II versus Placebo Treatment According to ACEi and ARB Exposure Status. A MAP from baseline to hour 3 in Angiotensin-II (blue) versus placebo (red) treated patients, stratified by ACEi and ARB exposure status. Boxes indicate mean, error bars SEM. B Total NED from baseline to hour 48. Points indicate median, bars interquartile range. For No ACEi/ARB (left), pRx indicates the p-value for the overall effect of Angiotensin-II treatment versus placebo. For ACEi (middle) and ARB (right), pint indicates the p-value for highest order interaction effect of ACEi or ARB with time and treatment, where p < 0.05 indicates an effect that significantly differs from the effect of treatment over time in the no ACEi/ARB group. C Study drug titration level over time. Boxes indicate mean, error bars SEM. P-values reflect longitudinal mixed effect model output as in B. Ang-II angiotensin-II, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, MAP mean arterial pressure, NED norepinephrine equivalent dose

Back to article page

Critical Care

ISSN: 1364-8535